WHO ICTRP trial
Efficacy and safety of subcutaneous dupilumab for the treatment of adult…
JPRN-jRCT2061220017 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2061220017 |
|---|---|
| Public title | Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) |
| Scientific title | Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO) |
| Primary sponsor | Tanaka Tomoyuki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Argentina;Japan;Canada;Japan;Italy;Japan;Korea;Japan;United States;Japan |
| Conditions | Pruritus |
| Interventions | Drug: Dupilumab (SAR231893) Pharmaceutical form: Injection solution, Route of administration: Subcutaneous Drug: Placebo Pharmaceutical form: Injection solution, Route of administration: Subcutaneous Drug: Fexofenadine (loratadine if not… |
| Registration date | May 19, 2022 |
| Target size | 208 |
| Secondary IDs | NCT05263206;2021-004315-76 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: